ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2914

The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort

Ruediger Mueller1, Toni Kaegi2, Sarah Haile3 and Johannes von Kempis4, 1Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 2Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 3Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland, 4Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Diagnostic criteria, Early Rheumatoid Arthritis, prognostic factors, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects VI: Impact of Treatment and Other Interventions

Session Type: Abstract Submissions (ACR)

Background/Purpose

To analyse whether early arthritis patients who do not fulfil the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) have a different course of the disease dependent on whether they can or cannot be classified as RA because of radiographic disease (as recently defined by the EULAR task force) at diagnosis. 

Methods

For this observational study within the Swiss RA cohort SCQM, we included patients with early undifferentiated arthritis (disease duration ≤1 year), as diagnosed by the treating rheumatologist, who had not received any previous DMARDs. 2010 ACR/EULAR criteria negative patients were separated into 2 groups (radiographic vs. non radiographic arthritis) depending on whether or not they had radiographic changes recently defined as erosive disease by a EULAR task force (≥3 joints with erosions). The primary outcome measure was the radiographic progression detected employing the Ratingen erosion score. HAQ and DAS 28 were used as secondary outcome measures. The average observation period was 4 years. 

Results

A total number 592 patients was analysed. 240 were not classifiable as RA by application of the 2010 ACR/EULAR criteria at baseline. 133 of these patients had radiographic arthritis and 50 non-radiographic arthritis. In 57 patients radiographs at the first visit were not available. Treatment was initiated in all patients with DMARDs, mostly MTX. There were no significant differences in the therapeutic strategies between radiographic and non-radiographic patients. No differences in DAS 28 and HAQ scores were found during follow up over 4 years. The average erosion scores were higher among patients with initially radiographic arthritis throughout the study. The progression of erosion scores over time, however, was higher in initially non radiographic arthritis patients (3.3 erosions/year vs. 0.4, resp., p<0.0001). 

Conclusion

The clinical and radiographic course of early undifferentiated arthritis under treatment was not dependent on the presence of erosions in 3 or more joints (i.e. the definition of radiographic disease by the EULAR taskforce) at diagnosis in our cohort.


Disclosure:

R. Mueller,
None;

T. Kaegi,
None;

S. Haile,
None;

J. von Kempis,

AbbVie, Antares Pharma, Bristol-Myers Squibb, MSD, Pfizer, Roche, and UCB,

5,

ristol-Myers Squibb, Roche, and UCB,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-clinical-and-radiographic-course-of-early-undifferentiated-arthritis-under-treatment-is-not-dependent-on-the-amount-of-erosions-at-diagnosis-results-from-the-swiss-prospective-observational-cohor/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology